The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2021 | MAIA: dara-len-dex demonstrates prolonged PFS in multiple myeloma
Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute and Atrium Health, Charlotte, NC, discusses results from the Phase III MAIA trial (NCT02252172), which is investigating daratumumab (dara) plus lenalidomide (len) and dexamethasone (dex) versus len-dex in patients with newly diagnosed multiple myeloma who are transplant-ineligible. At a median follow-up of 36.4 months, dara-len-dex demonstrated a prolonged progression-free survival (PFS) benefit, with median PFS not reached in the dara-len-dex arm. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx and Takeda; and has received speaking fees from Celgene, Janssen, Sanofi and Takeda.
